Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 5/20 | 0.65 |
| ▸ | FNTB | P49356 | 5/20 | 0.65 |
| ▸ | PGGT1B | P53609 | 2/20 | 0.65 |
| ▸ | GGPS1 | O95749 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6056470 | 1.00 | FNTA (0.65) | FNTAFNTBPGGT1BGGPS1KMT2A | |
| SCHEMBL11456515 | 0.93 | FNTA (0.54) | FNTAFNTBPGGT1BGGPS1 | |
| Squalene SCHEMBL27745343 | 0.85 | KMT2A (0.77) | GGPS1KMT2A | |
| Squalene SCHEMBL28409601 | 0.85 | KMT2A (0.77) | GGPS1KMT2A | |
| Squalene SCHEMBL27745351 | 0.85 | KMT2A (0.77) | GGPS1KMT2A | |
| Squalene SCHEMBL27769242 | 0.85 | KMT2A (0.77) | GGPS1KMT2A | |
| SCHEMBL15639481 | 0.82 | FNTA (0.75) | FNTAFNTBKMT2A | |
| SCHEMBL4783049 | 0.82 | FNTA (0.75) | FNTAFNTBKMT2A | |
| SCHEMBL8940773 | 0.82 | FNTA (0.53) | FNTAFNTBPGGT1BGGPS1KMT2A | |
| SCHEMBL4461665 | 0.81 | KMT2A (0.64) | FNTAFNTBPGGT1BGGPS1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006017369-A2 | USE OF A FARNESYL TRANSFERASE INHIBITOR IN THE TREATMENT OF VIRAL INFECTIONS | GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2006-02-16 | — | — | WO | disclosed |
| US-20020006967-A1 | METHODS OF TREATMENT OF OCULAR NEOVASCULARIZATION | CAMPOCHIARO PETER A (US) | 2002-01-17 | — | — | US | disclosed |
| US-5362906-A | Antitumor | MERCK & CO., INC. (US) | 1994-11-08 | — | — | US | disclosed |
| US-5298655-A | Enzyme inhibitors or anticarcinogenic agents | MERCK & CO., INC. (US) | 1994-03-29 | — | — | US | disclosed |
| EP-0534546-A1 | Farnesyl pyrophosphate analogs | MERCK & CO. INC. (US) | 1993-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020006967-A1 | METHODS OF TREATMENT OF OCULAR NEOVASCULARIZATION | GGT1, FNTA, PIGO | FNTA 2/4885FNTB 11/4885PGGT1B 407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.